Comment from Zhejiang Hisun Pharmaceutical Co., Ltd.

Summary: Zhejiang Hisun Pharmaceutical Co., Ltd. provides detailed technical feedback and specific questions regarding the proposed scale-up and postapproval change guidances. They advocate for clearer definitions of "same" equipment/SOPs, more nuanced classifications for site and batch size changes, and the inclusion of specific excipient categories and injection products in the guidance.